Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) CEO Sells $9,223,200.00 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR) CEO Nello Mainolfi sold 80,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $115.29, for a total value of $9,223,200.00. Following the sale, the chief executive officer owned 666,568 shares in the company, valued at approximately $76,848,624.72. This trade represents a 10.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Nello Mainolfi also recently made the following trade(s):

• On Wednesday, April 29th, Nello Mainolfi sold 30,000 shares of Kymera Therapeutics stock. The stock was sold at an average price of $81.18, for a total value of $2,435,400.00.

Kymera Therapeutics Trading Down 0.6%

Shares of NASDAQ KYMR traded down $0.69 during trading hours on Thursday, hitting $113.51. 788,284 shares of the company traded hands, compared to its average volume of 767,552. The stock has a market capitalization of $9.34 billion, a price-to-earnings ratio of -31.80 and a beta of 1.95. The company’s 50 day moving average price is $86.36 and its 200 day moving average price is $82.74. Kymera Therapeutics, Inc. has a 12 month low of $36.65 and a 12 month high of $130.05.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The company had revenue of $34.37 million during the quarter, compared to the consensus estimate of $8.27 million. During the same period last year, the company earned ($0.82) earnings per share. Kymera Therapeutics’s revenue was up 55.5% on a year-over-year basis. Equities analysts anticipate that Kymera Therapeutics, Inc. will post -3.28 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on KYMR shares. Loop Capital set a $97.00 price target on shares of Kymera Therapeutics in a report on Monday, June 8th. Truist Financial boosted their target price on Kymera Therapeutics from $116.00 to $136.00 and gave the company a “buy” rating in a research report on Monday. Bank of America upped their target price on Kymera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research note on Tuesday. Brookline Capital Markets reissued a “buy” rating on shares of Kymera Therapeutics in a research note on Monday, June 8th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $121.41.

Institutional Trading of Kymera Therapeutics

Large investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in Kymera Therapeutics by 6.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock worth $849,000 after buying an additional 1,833 shares during the period. Millennium Management LLC increased its holdings in shares of Kymera Therapeutics by 340.4% in the 1st quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock valued at $13,972,000 after acquiring an additional 394,562 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Kymera Therapeutics by 121.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock valued at $24,535,000 after acquiring an additional 491,737 shares during the period. Invesco Ltd. raised its position in shares of Kymera Therapeutics by 13.8% in the 2nd quarter. Invesco Ltd. now owns 47,884 shares of the company’s stock worth $2,090,000 after acquiring an additional 5,809 shares in the last quarter. Finally, Sei Investments Co. bought a new position in shares of Kymera Therapeutics in the 2nd quarter worth $265,000.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.